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A B S T R A C T
Europe has been at the forefront of efforts to control antibiotic resistance, and this globally important
health care problem has prompted numerous recommendations for action at both the national and
international levels. Starting in 2002, research on antimicrobial resistance has been considered to be one
of the specific objectives of the Sixth Framework Programme (FP6) within the European Union. This
report summarises the plenary presentations, as well as the findings of six Working Groups covering
specific areas of antibiotic resistance, given at a conference in November 2003 entitled ‘The Role of
Research in Combating Antibiotic Resistance’, co-organised by the European Union and the European
Society for Clinical Microbiology and Infectious Diseases, and held in Rome under the patronage of the
Italian government.
Clin Microbiol Infect 2004; 10: 473–497
I N T R O D U C T I O N
Infectious diseases are the second leading cause of
mortality in the world, resulting in c. 15 million
deaths annually [1]. The burden of bacterial
infections continues to rise because of changing
patterns of microbial aetiology, an increase in the
number of hosts with impaired immunity, the
ageing of Western populations, and the spread of
disease through globalisation and urbanisation. In
addition, the alarming emergence and spread of
antibiotic resistance among common pathogenic
bacteria threatens the effectiveness of therapy for
many infections. The spread of resistance to
multiple antibiotics among Streptococcus pneumo-
niae, Staphylococcus aureus, enterococci, Enterobac-
teriaceae and Pseudomonas aeruginosa is of
particular concern.
Europe has been at the forefront of efforts to
control antimicrobial resistance, and this globally
important health care problem has prompted
numerous recommendations for action at both
the national and international levels [2,3]. The
European Union (EU) has convened several
invitational conferences concerning resistance,
and published the Community Strategy Against
Antimicrobial Resistance [4] in 2001. This docu-
ment called for further research to improve our
understanding of the molecular mechanisms of
resistance, to develop new vaccines, antimicro-
bial agents and diagnostic tests, and to evaluate
strategies for resistance control.
Starting in 2002, research on antimicrobial
resistance was considered to be one of the specific
objectives of the Sixth Framework Programme
(FP6) within the EU. Accordingly, the DG
Research of the European Commission and the
European Society for Clinical Microbiology and
Infectious Diseases (ESCMID) co-organised a
conference entitled ‘The Role of Research in
Combating Antibiotic Resistance’ (28–30 Novem-
ber 2003). This conference, held in Rome under
the Patronage of the Italian government, had the
following aims:
• To clarify the state-of-the-art and research
priorities in fields where information is partic-
ularly needed, namely microbial ecology,
mechanisms of resistance, genomics and new
molecular targets for antibiotics.
• To identify the resistance topics most suitable
for European research and to contribute to the
establishment of the European Research Area
in this field.
• To stimulate partnerships across public, private
and governmental bodies for future research
initiatives.
• To identify ways of overcoming bottlenecks
in European research, such as those associ-
ated with decreasing industrial incentives
for research and development of new antibi-
otics.
• To increase the visibility of antibiotic research
among scientists, clinicians, politicians and the
general public.
• To contribute to the education of researchers
and public health officers in the specific field of
antibiotic resistance, and the means for its
control, through concerted research.
This report summarises the plenary presenta-
tions given at the Conference and the findings of
six Working Groups covering specific aspects of
antibiotic resistance.
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P L E N A R Y P R E S E N T A T I O N S
Introduction
The plenary presentations introduced many of
the main topics for consideration during the
Working Group discussions, namely the epi-
demiology of resistance, the impact of resistance
on human health, the evaluation of interven-
tions to control resistance, the role of the
pharmaceutical industry, and the means by
which European research can be stimulated
and co-ordinated.
Epidemiology of resistance
An improved understanding of the molecular
epidemiology of antibiotic-resistant bacterial
strains is central to efforts aimed at controlling
resistance. Research has been facilitated in recent
years by advances in genetic analysis, such as
multilocus sequence typing (MLST; http://
www.mlst.net), an unambiguous and highly dis-
criminatory method of characterising (or ‘geno-
typing’) isolates according to specific DNA
sequences [5]. As MLST data are portable
between laboratories, the method is particularly
suited to multicentre epidemiological studies,
e.g., those performed by the European Antimi-
crobial Resistance Surveillance System (EARSS)
[6]. However, the relatively high cost of MLST
analysis means that the use of this technique
should be confined to the sequencing of highly
variable genotypes.
It is hoped that the networking of MLST
systems will allow countries with low rates of
resistance to monitor prospectively the evolution
of resistant organisms, such as methicillin-resist-
ant S. aureus (MRSA). The international spread of
MRSA in hospitals is a major concern [7]. Accord-
ing to EARSS data, 22% of all S. aureus isolates
(n ¼ 18 726) from invasive infections between
1999 and 2002 in Europe were MRSA (Fig. 1) [6].
An increasing number of MRSA strains are
susceptible only to vancomycin and other glyco-
peptides, but decreased vancomycin susceptibil-
ity has now emerged in every MRSA lineage [8].
Eleven major clones of MRSA have been identi-
fied by MLST [9], and evolutionary relationships
between these clones have been inferred from
MLST and other genomic data by means of the
novel BURST (Based Upon Related Sequence
Types) program [9,10]. Further data on the spread
and evolution of MRSA will be gained from the
proposed Genetic Analysis of MRSA in Europe
(GAME) study. This collaborative study is inten-
ded to combine phenotypic and genotypic analy-
sis of MRSA isolates with information on
antibiotic prescribing guidelines, antibiotic use
and infection control practices, to allow prospect-
ive measurement of the effect of these activities on
MRSA epidemiology.
Recently, considerable epidemiological research
has been directed at the spread of MRSA in the
community setting, particularly in the USA [11].
MRSA strains in the community tend to be more
virulent than hospital clones. In particular, strains
that produce the Panton–Valentine leukocidin
cytotoxin are associated with severe skin infec-
tions and pneumonia [12]. MLST and other data
suggest that community-acquired MRSA clones
arise independently of local nosocomial strains
[13], although further research in this area is
required.
The evolution of resistance in Gram-negative
bacteria is also the subject of important research.
Escherichia coli is a species that evolves predom-
inantly in a clonal manner. Consequently, this
organism shows low genetic diversity, genetic
persistence and international clonal distribution.
E. coli acquires resistance primarily through the
spread of mobile genetic elements, i.e., integrons,
transposons and—most importantly—plasmids.
Plasmids carry genes coding for, for example,
various b-lactamase enzymes (e.g., TEM, SHV,
CTX-M and AmpC cephalosporinases). Further
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Fig. 1. Data from the European Antimicrobial Resistance
Surveillance System showing the proportion of invasive
Staphylococcus aureus isolates (n ¼ 18 726) collected
between 1999 and 2002 that were methicillin-resistant [6].
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research is required to investigate the origin of
these elements and, in particular, the possibility
of their transfer from poultry and livestock. Once
acquired, plasmids maintain their continued exist-
ence within cells through a variety of ‘addiction’
systems, toxin–antitoxin mechanisms, post-segre-
gational cell killing and restriction modifica-
tion systems. In view of these systems, and the
co-selection of multidrug resistance on plasmids,
research is required to determine the extent to
which resistance in E. coli can be reversed by
proper antimicrobial use. Also, there is a need for
more data relating resistance and virulence in this
species.
Other species, such as P. aeruginosa, evolve in a
predominantly panmictic manner, whereby DNA
exchange (or ‘recombination’) occurs between
cells. These species show high levels of diversity,
short-lived clonality and local or regional distri-
bution of clones. This ecological heterogeneity has
important implications for the evolution of resist-
ance and the assessment of measures to control
resistance. In addition to being intrinsically resist-
ant to many antibiotics, P. aeruginosa acquires
resistance through mutational up-regulation of
efflux pumps, derepression of AmpC b-lactamase,
and a reduction in the number of porin proteins.
Exposure to antibiotics favours the selection of
strains with a high mutational frequency (so
called ‘hyper-mutable’ strains). Oliver et al. [14]
showed that 36% of patients with cystic fibrosis
(n ¼ 30) were colonised by hyper-mutable strains
of P. aeruginosa. However, data from Germany
indicate that levels of fluoroquinolone usage and
resistance in P. aeruginosa can be correlated only
in strains with low genetic diversity (H. Grund-
mann, personal communication). Although these
data over-simplify the matter, they suggest that
ecological studies of the relationship between
antibiotic usage and resistance must be stratified
according to the genetic diversity of target path-
ogens.
Resistance and human health
Despite decades of research into the effects of
antibiotics, the risk posed to human health by
antibiotic resistance is poorly defined. Conse-
quently, current antibiotic policies are based
largely on precautionary principles. Clear quan-
tification of the risks of resistance would provide
a firmer basis for such policies and would aid
compliance among patients, physicians and other
stakeholders.
Research to quantify the clinical impact of
resistance is challenging. One theoretical
approach would involve a long-term ecological
experiment to assess the risk–benefit relationship
of antibiotic consumption. This study could be
based on longitudinal epidemiological studies,
such as the Framingham [15] and MONItoring
CArdiovascular disease (MONICA) [16] studies.
It would involve continuous monitoring of anti-
biotic usage, health outcomes and confounding
factors in appropriate population cohorts. A
conceptual framework for such a study has been
proposed under the title ‘Risk Evaluation and
Benefit Evaluation of Consumption of Chemo-
therapeutic Agents’ (REBECCA) (F. Baquero,
personal communication).
Interventions to control resistance
Little is known about the effectiveness of the
many types of interventions aimed at controlling
antibiotic resistance [17]. Recently, researchers in
the UK have evaluated systematically the evi-
dence supporting interventions to improve anti-
biotic prescribing in hospitals and isolation
policies in the hospital management of MRSA.
The analysis of hospital antibiotic prescribing
practice was conducted by members of the British
Society for Antimicrobial Chemotherapy, the UK
Hospital Infection Society and the Cochrane
Centre [18]. Of 360 intervention studies published
since 1980, 215 (70%) were excluded immediately
from the analysis because of an uncontrolled
‘before and after’ design or the collection of an
inadequate time series. A further 30 (10%) studies
were excluded subsequently because of various
methodological flaws (e.g., flawed control data or
randomisation procedures), leaving 61 (20%)
studies with eligible data. Although the quality
of published studies has improved in recent
years, this high exclusion rate indicates a consid-
erable waste of research resources and a need for
improved methodological training among
researchers.
The interventions evaluated by eligible studies
included ‘restrictive’ measures (e.g., automatic
antibiotic substitution or cessation orders) and
educational measures. Most were applied to the
selection of the antibiotic regimen; very few
studies have assessed interventions aimed at the
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initiation or cessation of antibiotics. Many studies
were unplanned analyses of measures instituted
to control resistance epidemics, and various flaws
were identified in the statistical methods used.
Antibiotic usage was the most common outcome
measure, with £ 30% of studies assessing health
care costs, resistance patterns or clinical out-
comes. Only eight studies recorded data on both
resistance and antibiotic usage, thereby allowing
correlations between these factors to be evaluated.
These data provide good evidence that reductions
in antibiotic usage can reduce resistance in mul-
tiply-resistant Gram-negative bacilli. Two studies
suggested that reductions in resistance could be
achieved in Clostridium difficile. However, there is
little evidence for the effectiveness of this kind of
measure in controlling MRSA or vancomycin-
resistant enterococci (VRE). A corresponding
analysis of interventions to control antibiotic
prescribing in ambulatory care is in preparation
(P. Davey, personal communication).
The review of isolation policies for the man-
agement of MRSA was conducted by researchers
at various UK centres [19]. Of 254 publications
screened, only 46 were included in the review.
Few of these were planned, prospective studies,
and only six provided interpretable data. The
results provided limited evidence for the effect-
iveness of single-room isolation and cohorting
measures, but conflicting evidence for isolation
wards.
There are several encouraging examples in
which interventions have been associated with a
reduction in resistance rates, although there is a
lack of good-quality data indicating that wide-
spread effects can be achieved or maintained [20].
The aforementioned systematic reviews provide
more information concerning ways to improve
research methods than on the effectiveness of
specific interventions. Changes in patterns of
microbial aetiology, resistance and medical prac-
tice have occurred since many of the primary
studies were performed. Hence, there is a need
for ongoing research, including prospective, well-
controlled studies comparing single and com-
bined interventions and the associated costs.
Standardised effect measures and reporting pro-
cedures for antibiotic prescribing interventions
are required to allow data to be compared and
pooled. This may be an objective that is well
suited for EU-supported research, as may be the
standardisation of routine infection control data.
Non-antibiotic approaches
Research into non-antibiotic approaches to anti-
infective therapy and prophylaxis declined sub-
stantially when antibiotics were introduced in the
1940s. Interest in these therapies increased with
the development of organ transplantation, the
occurrence of the HIV epidemic and, most
recently, the rise in antibiotic resistance. Non-
antibiotic approaches comprise pathogen-specific
methods (e.g., preventative and therapeutic vac-
cines, antibody therapies and adoptive cell trans-
fer) and non-pathogen-specific methods (e.g.,
biological response modifiers, replacement ther-
apy, augmentative therapy and immunoadju-
vants).
Prophylactic vaccines have had a limited effect
in reducing the disease burden from certain
bacteria, e.g., Strep. pneumoniae. However, no
vaccines exist for the pathogens in which bacterial
resistance is most threatening, i.e., Gram-negative
bacilli, P. aeruginosa, MRSA and VRE. The most
promising approach to novel therapeutic vaccines
is the development of DNA vaccines. For exam-
ple, adjuvant immunisation with a DNA vaccine
in mice infected with tuberculosis improved
immune responses and tissue eradication [21].
Antibody therapies have a potential role in the
prevention of disease (e.g., pneumonia) caused by
encapsulated pathogens, in the prevention and
treatment of sepsis (e.g., endotoxin neutralisa-
tion), in antitoxin treatment (e.g., botulism), in
post-exposure prophylaxis (e.g., tetanus, hepati-
tis), and in rapid protection against agents of
bioterrorism (e.g., anthrax toxins). The search for
pure antibody preparations has led to the devel-
opment of active peptide fragments and comple-
ment D regions. For example, Italian researchers
have produced an antibody peptide active against
a wide variety of bacterial and fungal pathogens
[22].
Biological response modifiers include cytokines
(e.g., colony-stimulating factors, interferons and
interleukins) and other natural and synthetic
compounds (e.g., thymosin-a1). Combination
therapy with thymosin-a1, a peptide responsible
for immune reconstitution in thymectomised ani-
mal models, improved survival when combined
with interferon and amantidine in a mouse model
of influenza [23]. Drotrecogin-a (recombinant
human activated protein C) reduced 28-day all-
cause mortality and appeared to be cost-effective
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in patients with severe sepsis [24,25]. Certain
antibiotics (e.g., macrolides) have shown cytoki-
ne-modifying effects that suggest a potential role
in chronic degenerative and atherosclerotic dis-
eases. However, routine use of antibiotics for such
conditions would add greatly to the selection
pressure for antibiotic resistance in bacteria,
suggesting a need for research to isolate the
anti-inflammatory properties of these agents from
their antibiotic effects.
Role of the pharmaceutical industry
Despite the pressing need for new antibiotics,
industrial research in this area is declining. Of
c. 400 candidate drugs currently under develop-
ment by pharmaceutical companies, only ten are
antibiotics (H. Labischinski, personal communi-
cation). The development of new antibiotics is
challenging and expensive. Typically, following
the identification of a new molecular target, it
takes > 2 years to produce a candidate antibiotic.
It takes a further 6 years and 800 million to
develop a compound for the market. Market
success rates are lower for new antibiotics than
for other drugs because of obstacles associated
with the chemistry and pharmacology of antibi-
otics, trends in clinical practice, regulatory
requirements, and the market within the bacterial
infection field.
The need for new antibiotics will be fulfilled
only through a partnership between health care
authorities, academia and the pharmaceutical
industry. It may be worthwhile for industry to
work with health authorities to contribute to high-
quality research into the optimisation of current
antibiotic usage and infection control. Both meas-
ures may help to control resistance and, in the
long term, extend the commercial life of antibiot-
ics. Other measures needed to reverse the indus-
trial decline in research and development include
the prioritisation of research and the development
of incentives.
European research: 6th Framework Programme
(FP6)
Europe is a leading region for the biological and
pharmacological research upon which drug
development is based. However, there is insuffi-
cient investment allocated to the critical develop-
ment stages between basic research and the
pharmaceutical market. The European Research
Area is a joint effort by the EU and Member States
to address structural deficits in European
research. The FP6 is the first venture to be
initiated under this scheme.
The FP6 has launched several new instruments
to support European research. ‘Networks of
Excellence’ are designed to promote excellence
within a particular research area and to address
the fragmentation of research by linking resources
and expertise around a joint programme of
activity. ‘Integrated Projects’ generate the know-
ledge required to implement defined priorities by
integrating resources to achieve clearly defined
scientific and technological objectives. Both types
of initiative are selected through open calls for
proposals and peer review. Networks of Excel-
lence are funded for ‡ 5 years, while Integrated
Projects are funded typically for 3–5 years. Addi-
tional supportive instruments include ‘Specific
Targeted Research Projects’, which fund research
activities of a more limited scope, ‘Coordination
Actions’ promoting networking, and ‘Specific
Support Actions’, which fund information and
communication activities (e.g., conferences).
The FP6 has a total budget of 17.5 billion. Of
this, 2.255 billion is allocated to ‘Life Sciences,
Genomics and Biotechnology’, the first of seven
thematic priorities. Within this priority, ‘Applica-
tion-orientated genomic approaches to medical
knowledge and technologies’ includes research
on combating resistance to antibiotics and other
drugs. There is also scope for research on the
public health aspects of drug resistance under the
heading ‘Supporting policies and anticipating
scientific and technological needs’, within a
cross-cutting priority entitled ‘Specific activities
covering a wider field of research’.
The first call for proposals under the FP6,
launched in 2002, resulted in the funding of four
projects concerning antibiotic resistance (Table 1).
The second call, which closed in November 2003,
invited proposals for new integrated projects in
two topics relevant to antimicrobial resistance:
‘Functional genomics of antibiotic-producing
organisms’ and ‘New molecular targets for the
development of drugs against pathogens causing
severe resistance problems’. In addition, there
was a call for specific targeted research projects or
concerted actions under the topic ‘Novel approa-
ches to address antimicrobial resistance through
non-antimicrobial based therapies’. Proposals
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submitted under this call are being assessed
currently.
Proposed topics for the two remaining calls for
proposals (the third and fourth calls) are currently
open to discussion and suggestions from the
scientific community. Topics that may be consid-
ered in one or the other of these calls include:
management of respiratory tract infections;
nosocomial infections; functional microbial
genomics; fungal resistance; and the transmission
of resistance between animals and humans.
W O R K I N G G R O U P 1 : M I C R O B I A L
P O P U L A T I O N B I O L O G Y A N D
E C O L O G Y O F R E S I S T A N C E
Introduction
Extensive release of antimicrobial agents in all
environments (i.e., both in hospitals and in the
community) during recent decades has had an
important impact on microbial populations. Pa-
tients, healthy persons, animals and the general
environment have become important reservoirs
for resistant bacterial populations and resistance
genes. Bacteria have developed resistance mech-
anisms through mutations of pre-existing genes or
have gained additional genes through horizontal
gene transfer (HGT). Both evolutionary processes
have contributed to the enrichment of the resist-
ance gene pool, thereby enhancing the opportun-
ities for the persistence and transmission of
antimicrobial-resistant bacteria and resistance
determinants. As a result, resistance is now docu-
mented in bacteria that, traditionally, were fully
susceptible. In addition, multidrug-resistant bac-
teria have risen to prominence, and new ‘oppor-
tunistic’, and often multidrug-resistant, organisms
are recognised increasingly as important patho-
gens in both the nosocomial and community
settings.
The assembly of resistance-related genetic ele-
ments probably originated from heterologous
sources in various organisms, including pathogens
and other bacteria belonging to the normal microb-
iota. These elements have acted as extremely
efficient amplifiers for the evolution of resistance.
It has been demonstrated, both in Gram-positive
and in Gram-negative bacteria, that resistance
genes may persist in well-adapted clones in a
particular niche, and that they may spread to other
clones of the same or different species as a conse-
quence of gene mobilisation. These new clones may
share the same niche, but may also explore and
Table 1. Research proposals on antimicrobial resistance selected from the first call for proposals under the European
Commission 6th Framework Programme (FP6) in 2003
FP6 research topic Project title Project type Project scope FP6 contribution ( ) Start date
Testing antiviral drug
resistance and
understanding
resistance
development
European Vigilance Network
for the Management of
Antiviral Drug Resistance
(‘viRgil’)a
NoE Network system to
predict and monitor
resistance in HBV,
HCV and influenza
9 million Spring 2004
Basic mechanisms
behind resistance
Molecular mechanisms
behind resistance to
inhibitors of cell-wall
synthesis (‘COBRA’)
STREP Modification of
cell-wall synthesis
in Staphylococcus
aureus,
Streptococcus
pneumoniae and
enterococci, and
production of
b-lactamases in
Gram-negative
organisms
3 million February 2004
Basic mechanisms
behind resistance
Molecular mechanisms
of resistance, virulence
and epidemicity in
Strep. pneumoniae
(‘PREVIS’)
STREP Survival and growth
of Strep. pneumoniae
in antibiotic-rich
milieu and inter-species
competition for
colonisation and
spread
3 million January 2004
Workshop on how to
address antimicrobial
resistance by
exploiting microbial
genomics
‘Micro-MATRIX’
meeting (Spain)
SSA Strategies to address
antimicrobial
resistance through
the exploitation of
microbial genomics
34 000 17–20 April 2004
aContract still under negotiation.
HBV, hepatitis B virus; HCV, hepatitis C virus; NoE, Network of Excellence; SSA, specific support actions; STREP, Specific Targeted Research Projects.
See text for explanation of project types.
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colonise new environments, increasing the likeli-
hood that the resistance genes will become fixed in
the bacterial population, and that bacterial evolu-
tion will progress towards resistance [26].
An accelerated evolution of bacterial resistance
is being observed currently. Some of the processes
involved in this progression are starting to be
understood, but various factors affecting the
ecology of resistance and the evolution of resist-
ant populations need to be addressed. These
factors can be clustered into two groups:
• Intrinsic factors of bacterial populations—
including the bacterial fitness cost associated
with resistance, as well as the mechanisms
leading to the assembly of genetic elements
involved in resistance evolution, including the
superimposition of virulence determinants.
• External factors influencing the bacterial popu-
lation—including vaccination, immunoselec-
tion, antibiotic use and other interventions,
both in patients and in the food chain (Fig. 2).
Intrinsic variables
Cost of resistance and the influence of mutators
Resistance has an important biological cost for
bacteria, in terms of reduced fitness. This is a key
parameter in understanding the stability and
potential reversibility of resistance [27]. The
advantage associated with resistance, whether
originating from mutation or recombination,
may be limited by the cost associated with the
presence of mutated genes or newly acquired
genes. The cost of resistance is negligible com-
pared with the advantages of resistance in the
presence of antibiotics. In the absence of antibiot-
ics, resistant bacterial populations may be super-
seded by susceptible populations because of the
fitness cost associated with resistance. Resistant
bacteria might also retain resistance in the
absence of antibiotics by compensating for the
biological cost of resistance via new compensa-
tory mutations or gene exchange. Some of these
compensatory advantages may correspond to
virulence determinants or other functions permit-
ting resistant bacteria to adapt to different habi-
tats or environments, including those conditions
generated by the immunological system.
Studies are needed to determine the importance
of the biological cost of resistance and associated
compensation mechanisms in resistant popula-
tions, and to understand clearly the role exerted by
antibiotics in these processes. In-vitro models are
required to identify environmental conditions that
influence the emergence and maintenance of
secondary mutations and ⁄ or the acquisition of
new genes compensating for the fitness cost.
Moreover, factors eliminating ancestral, suscept-
ible sub-populations within resistant populations
must be researched. These factors should be
investigated in different conditions and environ-
ments with the assistance of mathematical mod-
elling. Furthermore, no data exist on the interplay
of the immunological system with these processes.
Under long-term sequential antibiotic selective
pressure, bacterial populations may accumulate
multiple mutations. This effect has been described
clearly in stable mutator Gram-negative bacilli
and, to a lesser extent, in Gram-positive bacteria.
Mutators may achieve a mutation rate up to
200-fold higher than that in normal bacterial
populations, frequently by alterations in the
DNA mismatch repair system. The transition
from ‘normo-mutable’ to mutator status may be
accelerated under environmental pressures, inclu-
ding those exerted by antibiotics. As a conse-
quence, cumulative mutations yield resistant
bacteria with multidrug-resistant phenotypes.
Mutator genes are more prevalent in ‘chronic
coloniser’ pathogens, but their presence has not
yet been explored in efficient epidemic strains or
endemic populations. Mutator genes are likely to
induce deleterious mutations, presenting an indi-
rect selective disadvantage for the bacteria. How-
ever, periodic selection and genetic compensation
processes may contribute to the stabilisation of
mutator strains. Moreover, certain mutators are
more proficient than normal strains at HGT and
Ecology of R
Evolution of R
Gene variation
gene transfermutation
nosocomialcommunity
Host population / reservoirs
- commensals
- healthy carriers
environment
Intrinsic variables
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Fig. 2. Intrinsic and external factors affecting the ecology
of bacterial resistance and the evolution of resistant
populations.
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recombination, which may contribute to the per-
sistence of resistance genes and resistant strains.
The use of mutators in fitness cost experiments
may help to accelerate an understanding of this
parameter and its influence on the irreversibility
of resistance.
The potential benefits of an increased mutation
rate for adaptation—without the continuous costs
of deleterious mutations—have been reviewed
recently [28]. This effect arises only under stress
conditions in so-called ‘transient’ or ‘inducible’
mutators. In these populations, the hyper-mutator
phenotype is recognised only in the presence of
antibiotics. However, it may be reversed by the
depletion of mechanisms involved in mutagenesis
systems or by recombination with wild-type
mismatch repair alleles in the absence of stress
conditions. Further studies are needed to eluci-
date the importance of mutators in the develop-
ment and maintenance of resistant populations.
Mechanisms of genetic assembly
Traditionally, plasmid exchange was considered to
be the most important mechanism for the mobili-
sation and spread of resistance determinants.
Sequence analysis of genomes has now revealed
the importance of other genetic elements in the
spread of newly detected determinants, such as
those carrying genes encoding carbapenemases,
non-classic extended-spectrum b-lactamases (e.g.,
CTX-M enzymes), plasmid-mediated AmpC
enzymes, plasmid-mediated fluoroquinolone
resistance in Gram-negative bacteria, and resist-
ance to tetracycline, macrolides and vancomycin in
Gram-positive species. Most genes encoding these
determinants are inserted in complex structures
resulting from the assembly of different genetic
pieces, often from different ancestors [29]. Active
research to identify and describe these structures
and their integrative elements is underway. This
research aims also to scrutinise the epidemiology of
these factors in different bacterial hosts and their
distribution in different environments. However,
there have been fewer attempts to understand the
specific mechanisms leading to the assembly of
these components into complex constructions, and
the way in which these constructions are preserved
within bacterial populations.
Virulence determinants and resistance
The interplay between virulence and resistance
phenotypes in the maintenance of single bacterial
cells and bacterial populations should influence
future networks of research. Virulence mecha-
nisms may be acquired in non-virulent popula-
tions as a consequence of evolutionary processes.
Such processes include mutations and the con-
struction of pathogenicity islands by genetic
recombination [30]. In common with resistance,
virulence may also have an important biological
fitness cost for bacteria.
Continuous antimicrobial challenges to well-
adapted, virulent bacterial populations may faci-
litate the persistence of resistance. Conversely, the
acquisition or expression of virulence determi-
nants by resistant bacteria may contribute to per-
sistence of virulence. In both cases, the resulting
virulent and resistant clones are capable of
spreading to different environments and hosts.
Virulence and resistance determinants may be
linked in efficient transmissible elements. In
this case, a polyclonal structure of virulent and
resistant populations can be expected to arise.
Different examples have been shown among
Gram-positive organisms, including community-
acquired Panton–Valentine leukocidin-producing
MRSA strains, and enterococcal surface protein-
producing multiresistant strains of Enterococcus
faecalis and Enterococcus faecium.
Similar approaches are used by other patho-
genic bacteria [31], but these require further
research. The balance between virulence and
resistance features, with regard to the different
levels at which bacterial populations adapt to
various environments or hosts, may lead to future
interventions to control resistance.
External variables
Vaccination and immunoselection
Vaccination has an important impact on bacterial
populations, leading to a potential decrease in the
number of pathogenic bacteria. Moreover, vaccin-
ation programmes benefit not only the vaccinated
human population, but also individuals who are
not vaccinated. In the case of typical respiratory
tract pathogens able to produce invasive diseases,
such as Strep. pneumoniae and Haemophilus influen-
zae, vaccination has influenced the distribution of
bacterial serotypes. Drastic reductions in certain
serotypes have been associated with decreases in
resistance [32]. However, this modification has
also led to the emergence of other rare serotypes,
and it may be responsible for the increase in
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certain resistance mechanism variants that were
previously in a minority. Thus, the influence of
vaccination on microbial population biology and
the ecology of resistance, particularly on specific
(multidrug) resistant clones, should be a priority
in research on combating antibiotic resistance.
The importance of immunoselection of bacterial
populations by hosts, and the influence of this
process on the presentation of disease, is begin-
ning to be understood. The effect of immunose-
lection on antimicrobial resistance still requires
study. Some of the factors involved are certainly
related to bacterial colonisation and ⁄ or persist-
ence abilities, and also to the limitations of the
immune system in eliminating these bacteria. This
has been shown with specific populations of
Neisseria meningitidis and Helicobacter pylori. In
situations of immunological tolerance, the per-
sistence of bacteria during antibiotic challenge
influences development of resistance. Interest-
ingly, the effect of immunoselection on organisms
belonging to normal microflora has not been
studied to the same extent, and there has been
little research on the distribution of resistant
populations and the net balance of resistance
determinants and gene structures for gene trans-
fer within these populations.
Antibiotic consumption and infection control
The incremental relationship between increased
antibiotic consumption, in both humans and
animals, and the selection of resistant organisms
has been documented many times, and has been
the subject of previous European conferences.
Conversely, a decline in antibiotic use is expected
to decrease the prevalence of resistant bacterial
populations. However, in some cases, the pres-
ence or fixation of the resistance genes in specific
structures has rendered attempts to decrease
resistance unsuccessful [33].
There are well-documented differences
between European countries in terms of resist-
ance patterns and antibiotic consumption. In
addition to resistance surveillance, studies of
interventions designed to control resistance are
required. Attempts have been made to control the
spread of extended-spectrum b-lactamase (ESBL)-
producing organisms, AmpC b-lactamase-hyper-
producing Enterobacter spp. and P. aeruginosa,
MRSA, and macrolide and ⁄ or b-lactam-resistant
Strep. pneumoniae and Strep. pyogenes. However,
more specific study designs should be used to
demonstrate the modification of resistant bacteria
population structures by these interventions.
Moreover, the influence of reducing individual
exposure to antibiotics on the availability of the
resistance gene pool, particularly those genes and
vectors participating in HGT, needs to be inves-
tigated in man, in both the nosocomial and
community settings, and in animals. Furthermore,
the impact should be evaluated on both patho-
genic organisms and the normal microbiota.
Again, the use of mathematical models may
benefit the design of such studies [34].
A closely related area of interest concerns the
impact of new antibiotics on bacterial popula-
tions. This effect should be monitored in surveil-
lance studies to ascertain the emergence of
bacteria resistant to these new antibiotics, and to
assess the effect of new antibiotics on the ecology
of resistance determinants. Active surveillance
procedures for sentinel studies should be de-
signed to research these relationships.
Infection control measures may reduce the
transmission of resistant organisms, and thereby
decrease the absolute pool of resistant bacteria
and the gene pool of resistance determinants. This
has been investigated recently by tracing integron
structures, and further research should investi-
gate other gene-capture units participating in
HGT, such as phage-like structures.
The identification of co-selection factors for
resistant populations and the maintenance of
resistance determinants should also be studied.
These factors include non-antibiotic challenges,
such as exposure to heavy metals, toxic chemicals,
organic solvents, household disinfectants and
non-antimicrobial drugs. Some of these chal-
lenges may occur in the environment, and may
be important in favouring the assembly and
evolution of different mobile elements.
Probiotics, prebiotics, synbiotics and food chain
modifications
There is renewed interest in Europe in the use of
probiotics, prebiotics and synbiotics, in the hope
that they may benefit mucosal immunoresponse
and prevent bacterial infections. Prebiotics are
chemicals used mainly to manipulate the compo-
sition of colonic microbiota, and improve health
by stimulating colonisation with probiotic bac-
teria. Probiotics are non-pathogenic bacteria that,
when ingested or applied to mucosal surfaces, are
expected to benefit host health or physiology. The
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combination of prebiotics and probiotics is de-
fined as ‘synbiotics’, which represents a new field
of investigation. These strategies are used to:
prevent bacterial infections, mainly in the gastro-
intestinal tract (including those produced by
H. pylori); regulate the mucosal immune response;
avoid intestinal inflammation; and prevent aller-
gic reactions. Prebiotics and probiotics are also
used in animals, particularly since the use of
antimicrobial agents as growth promoters has
now been limited.
Prebiotics and ⁄ or probiotics should be intro-
duced only after a risk assessment of their effects
on normal bacterial populations in humans,
animals and the environment. The potential
production of toxins and virulence factors affect-
ing bacteria and hosts should be investigated
carefully. In addition, standardised studies are
needed to elucidate their clinical usefulness and
the mechanisms responsible for any beneficial
effects. The direct influence of probiotics and
prebiotics on natural mucosal bacterial popula-
tions, and the interactions between these agents
and the immune system, should also be re-
searched [35].
A potential risk associated with the use of
probiotics is the transfer of resistance determi-
nants from these bacteria to normal microbiota.
This effect should be monitored carefully in
humans and animals. Moreover, the potential
transfer to humans, through the food chain, of
probiotic organisms used in animal husbandry
and food technology should be evaluated. The
potential resistance gene transfer processes
should be evaluated, as well as the resulting
impact on bacterial populations. Gaps in know-
ledge in this area include an absence of microbio-
logical breakpoints and few quantitative and
qualitative data on HGT of antibiotic resistance
genes to organisms used in food technology.
Tools for research and endpoints
Future studies into microbial population biology
and the ecology of resistance should be stratified
into descriptive, predictive and intervention stud-
ies. Descriptive research should use quantitative
ecological methods. In addition, new technologies
for comparing population genomics should be
introduced to search for resistance determinants
and to identify genomic structures involved in
HGT. These studies should be performed using
time-series comparisons to elucidate evolving
phylogenies. Moreover, predictable, fitter strains
able to spread readily in the population should be
included as indicators within descriptive studies.
Predictive studies should use mathematical mod-
els to predict the emergence and persistence of
individual resistant bacteria within populations,
and the evolution of these strains. The use of
mathematical modelling to predict modifications
of genetic determinants, including mutation and
recombination processes, will also contribute to
an understanding of the ecology of resistance.
Observational studies are important to improve
overall knowledge of the problem of resistance
and to develop control strategies, but intervention
studies are mandatory for ascertaining the impact
of these strategies. The emergence, persistence
and modification of individual bacteria, bacterial
clones, resistance gene carriers and resistance
determinants should be the endpoints for each of
these three types of research.
Conclusions
The application of microbial population biology
to the study of the ecology of antibiotic resistance
is a newly introduced strategy which should be
understood in terms of the evolution of bacterial
populations and the genetic determinants respon-
sible for resistance. The targets for this research
comprise individual bacteria, bacterial clones,
bacterial population communities in different
hosts and environments, individual resistance
genes, and genetic structures carrying resistance
genes that participate in HGT. The investigation
of internal and external factors affecting these
targets requires differential research strategies to
allow identification of the mechanisms involved
in the emergence of resistance, together with their
means for dissemination and persistence within
bacterial populations. Descriptive, predictive and
intervention studies in this area will help to
combat antibiotic resistance.
W O R K I N G G R O U P 2 : T H E C L O N A L
S P R E A D O F R E S I S T A N T B A C T E R I A
I N E U R O P E
Introduction
The key issues discussed in this Working Group
were the clone concept, the geographical expan-
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sion of resistant bacterial clones in Europe, the
role of mobile elements in the development and
spread of drug-resistant clones, the technology
and concepts applicable to the molecular epi-
demiology of resistant clones as a guide to
infection control, and the role of laboratory
support for international communicable disease
surveillance.
The Working Group developed five statements,
each presented below with supporting commen-
tary.
Evolution and fitness of resistant clones at the
bacterial cell level
Bacterial population genetics indicate that many
human pathogens are composed of a limited
number of successful clonal lineages which share
conserved genetic elements involved in patho-
genicity and resistance to antibiotics. These bac-
terial lineages, and the associated stable genetic
elements, can be viewed as mosaics of clonal
selection and evolution. Certain clinically signifi-
cant multidrug resistance problems arising
worldwide (e.g., b-lactam-resistant Strep. pneumo-
niae and MRSA) are related, in part, to the
international dissemination of epidemic clones
that have accumulated several resistance traits.
These clones have been shaped within the bac-
terial species through an evolutionary process
that includes: (1) the selection of prevalent strains
more proficient than others in colonisation ability
or virulence; (2) the integration in these strains, by
HGT, of resistance gene elements or whole resist-
ance islands; (3) mutations conferring additional
resistance traits; and (4) mutations that compen-
sate for the energetic cost of these genetic alter-
ations, and thereby restore the biological fitness of
the cell.
Dissemination by HGT of mobile elements is
itself a major driving force in the evolution of
bacterial populations towards resistance. Plas-
mids and non-replicative elements, such as
conjugative transposons, are exchanged effi-
ciently between bacteria. Transduction and nat-
ural transformation are also efficient means of
resistance acquisition in some species. Finally,
integrons favour the accumulation and stabili-
sation of resistance genes in a single bacterial
host, and thereby contribute to the regulation of
their expression. Together, these elements con-
stitute a powerful ‘toolbox’ that makes possible
virtually unlimited dissemination of almost any
resistance gene throughout the bacterial world.
Studies that include investigations on the
molecular epidemiology of mobile genetic ele-
ments contribute significantly to a comprehen-
sion of the clonal spread of antibiotic resistance.
This approach has been used sucessfully to
study the dissemination of ESBLs in different
phylogenetic groups of E. coli and in different
species of enterobacteria (e.g., TEM-4, TEM-24,
CTX-M-9). Researchers have been able to differ-
entiate between several distinct paths of evolu-
tion, i.e., those characterised by few clones with
a single resistance gene-carrying plasmid (inter-
national clones), by many clones with a single
resistance gene-carrying plasmid, or by many
clones with a single resistance gene-carrying
transposon integrated in different plasmids (e.g.,
Canton et al. [36]).
Statement 1
The integrated study of all elements of bacterial
evolution, including the core genome, pathogen-
icity islands, resistance islands, resistance genes,
resistance mutations and compensatory muta-
tions, together with an assessment of fitness by
in-vitro (competition assays) and in-vivo (animal
model) studies, will improve greatly our under-
standing of the successful adaptation of prevalent
clones. Specific attention should be paid to the
study of mobile genetic elements involved in the
evolution of resistant clones (i.e., their origin,
diversity, mode of assembly, mechanisms of
transfer and classification) in order to yield a
comprehensive picture of the spread of antibiotic
resistance.
Methods for clonal detection and
characterisation
Numerous molecular epidemiological surveys
have delineated the widespread expansion in
Europe of antibiotic-resistant clones of Gram-
positive organisms such as penicillin-resistant
pneumococci, MRSA (including specific clones
susceptible to gentamicin or producing Panton–
Valentine leukocidin), glycopeptide-resistant Ent.
faecium, Mycobacterium tuberculosis resistant to
rifampicin and isoniazid, as well as Gram-neg-
ative organisms such as ESBL-producing entero-
bacteria, P. aeruginosa, and Salmonella enteritidis
(e.g., Lelievre et al. [37]). However, these surveys
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relied on methods with variable discriminatory
power and ability to characterise resistant
clones.
In practice, the results of phenotypic methods,
such as antibiotic susceptibility testing, could be
used to detect particular resistant clones, provi-
ded that these methods are designed adequately
(i.e., in terms of the drugs to be tested, mode of
expression of the results, definition of the pat-
terns, etc.) and that their discriminatory power is
assessed. Genotyping by pulsed-field gel electro-
phoresis or single-loci sequencing can be extre-
mely effective in studying outbreaks at a local
level, whereas PCR-based systems that rely on
observations of genomic sequence polymor-
phisms at multiple loci can be used at a later
stage to inform surveillance programmes. Multi-
plex PCR, binary probe typing and DNA
microarrays constitute high-throughput technol-
ogies suitable for characterising resistant clones
at this macro-epidemiological level [38]. It would
be useful to build databases of international
epidemic clones of major resistant pathogens. If
such data bases were updated regularly, DNA
microarrays could be designed and applied to
screen patients for these clones upon hospital
admission.
Statement 2
Progress should continue to be made in the
harmonisation of genotyping methods and
nomenclature. The markers obtained by these
methods should be integrated into European
surveillance programmes on communicable dis-
eases and bacterial resistance. The most cost-
effective and polyvalent techniques should
be favoured and validated by pilot studies.
Databases of genetic markers of major interna-
tional resistant bacterial clones should be estab-
lished. It should be recognised that such schemes
require investment in many countries to make
first-screen and reference typing services avail-
able more widely to hospital resistance surveil-
lance and infection control programmes.
New tools to study the dynamics and expansion
of resistant clones
New combined typing systems based on
genomic sequencing can provide comprehensive
and phylogenetically relevant information on
multiresistant clones, such as MRSA. These
systems allow investigation of the evolutionary
history of successful clones at national or
international level, e.g., community-acquired
MRSA clones carrying the Panton–Valentine
leukocidin gene that have evolved from ST30
methicillin-susceptible S. aureus [9]. The integra-
tion of results of molecular epidemiological
research into mobile elements and resistance
determinants, based on genome typing systems
involving analysis of amplified fragment-length
polymorphisms, single-nucleotide polymor-
phisms, variable number of tandem repeats or
microarray profiling, will be of great help in
elucidating the dynamics of major successful
clonal complexes such as B2 E. coli (EXPEC),
CC30 MRSA and CC1 Ent. faecium. This type of
integrated approach can also be used to investi-
gate the accumulation of resistance elements in
particular clones (e.g., M. tuberculosis resistant to
rifampicin and isoniazid).
Many factors interact to determine the spread
and persistence of resistant clones in humans,
animals and the environment. These factors
relate to the host (e.g., previous hospitalisation,
antibiotic therapy, the number of persons at
home), the pathogen (e.g., virulence, resistance
traits) and antibiotic use. Mathematical models
are being developed to study and quantify in a
predictive manner the respective roles of these
factors in the dynamics of resistance at the
population level.
Statement 3
New genome-based tools should be used to
study the dynamics and expansion of resistant
bacterial clones. Integrated and combined typing
systems based on genomic sequencing will
help to elucidate the evolution of major suc-
cessful clonal complexes. Again, mathematical
models will help to assess the respective roles
of the factors (e.g., host, pathogen, antibiotic
pressure) that co-determine the spread and
persistence of resistant clones, and to predict
the dynamics of resistance at the population
level.
Statement 4
Well-defined communities in which host move-
ments and interrelations between hosts are
limited sufficiently to allow accurate investiga-
tions—such as hospitals or hospital units (e.g.,
intensive care units), nursing homes, schools or
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small rural areas—provide opportunities for
measuring the prevalence of successful clones at
the population level and for studying the factors
modulating their spread, such as environmental
factors (e.g., antibiotic use), host factors, bacterial
factors and genetic elements.
Epidemiology of resistant clones at the local,
regional, national and global levels
Numerous surveillance systems based on local,
regional, national or international networks (or
networks of networks) are devoted to, or at
least involved in, antibiotic resistance monitor-
ing. When properly organised, such surveillance
can estimate the prevalence or incidence of
resistance, with the surveyed population as a
denominator (i.e., through ‘enhanced surveil-
lance’, as recommended by the World Health
Organisation (WHO)). The EARSS is developing
this approach at a European level. These sys-
tems constitute a potential basis for organising
epidemiological studies that target successful
clones or clonal complexes. Such studies can
be used to assess parameters that modulate
clonal spread, thereby allowing these data to be
integrated within predictive models. A well-
defined sentinel scheme for sampling repre-
sentative isolates at a local laboratory level
needs to be designed. Two-stage genotyping
(as described above) would be a cost-effective
means to identify important clones and to
compare their distribution over time and place
in the population surveyed. National refer-
ence centres that conduct multicentre antibiotic
resistance surveillance and alert programmes
can play a pivotal role in this process, and
should be linked in European networks, where
available.
Statement 5
Efforts should be made to integrate data regard-
ing clonal type frequency distribution for major
bacterial pathogens more efficiently by means of
existing surveillance systems dedicated to anti-
microbial resistance. This integrated European
system should be developed by involving and
networking the available national reference cen-
tres. It should enable early detection and warning
of emerging epidemic multidrug-resistant clones
that warrant immediate control.
W O R K I N G G R O U P 3 :
A N T I M I C R O B I A L D R U G
D I S C O V E R Y — E X P L O I T I N G
M I C R O B I A L G E N O M I C S A N D
C O M B I N A T O R I A L C H E M I S T R Y T O
F I N D N E W M O L E C U L A R T A R G E T S
Introduction
The development of new antimicrobial agents
during the last 10 years has been characterised by
a high degree of activity within the fields of
antiviral agents, antifungals and antibiotics active
against Gram-positive bacteria. The main reasons
for this are the HIV ⁄AIDS epidemic, the increas-
ing number of immunodeficient patients, and the
rapid increase of infections caused by multidrug-
resistant organisms such as MRSA, penicillin-
resistant Strep. pneumoniae and VRE. However,
during the same period, there has also been a
marked increase in clinically important antibiotic
resistance in Gram-negative bacteria, e.g.,
ESBL-producing Enterobacteriaceae and carbape-
nem-resistant, non-fermenting organisms such as
Acinetobacter spp., Pseudomonas spp. and Burkholde-
ria spp. Despite this, there are no new antibiotics
in clinical development that have satisfactory
activity against such organisms, and very few
compounds in preclinical evaluation. Other micro-
organisms of major clinical importance for which
there is a lack of new and improved treatments are
M. tuberculosis strains resistant to rifampicin and
isoniazid. There is also a lack of agents with
documented activity against many microbes that
may be used for bioterrorist purposes, in particular
the smallpox virus.
Obvious reasons for this worrying situation
include the extremely high cost of developing
new antimicrobial drugs, and the tendency for
clinicians to keep new antibiotics in reserve in
order to reduce the risk of worsening resistance.
In the case of M. tuberculosis, a major problem is
that resistant strains are most common in devel-
oping countries, which cannot afford the costs of
newly developed drugs. These factors have
resulted in a limited economic incentive for
pharmaceutical companies to initiate research
aimed at finding new treatment modalities for
infections.
Obstacles to be overcome during the develop-
ment of a new antimicrobial agent are the
requirement for activity against multiple targets
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(especially for antibiotics), large microbial popu-
lations that give rise to a high likelihood of
resistance mutations, and the possibility of hori-
zontal transfer of resistance genes between micro-
organisms. Approaches to the identification of
new agents include the screening of natural
products, revisiting old chemical structures, and
microbial genomics.
Screening of natural products
b-Lactams and many other antibiotics are the
result of screening for naturally occurring prod-
ucts with antibacterial activity. Although such
methods proved highly successful in the past,
they are now being abandoned because they are
cumbersome and expensive. Moreover, it is likely
that the most common natural products with
antimicrobial (or at least antibacterial) activity
have been identified already.
Revisiting old chemical structures
Many candidate antimicrobial compounds have
been withdrawn from full clinical development
because they showed unfavourable animal toxic-
ity profiles, resistance problems or pharmacoki-
netic disadvantages, such as poor solubility of
parenteral drugs and insufficient oral absorption.
It is likely that these problems could be overcome
for some products. b-Lactamase inhibitors, such
as clavulanic acid and sulbactam, have overcome
some of the problems associated with the degra-
dation of penicillins and cephalosporins by
b-lactamase enzymes. Examples of chemical alter-
ations increasing the gastrointestinal absorption
of antimicrobials include esterification (e.g., piv-
mecillinam, cefpodoxime proxetil and valacyclivir)
and various types of enterocoating to prevent the
inactivation of erythromycin by gastric acid.
Another example of the positive effects of chem-
ical modification is imipenem, or N-formimidoyl
thienamycin, a considerably more stable and
soluble molecule than thienamycin itself. This
antibiotic also exemplifies the chemical modifica-
tion of an unfavourable pharmacokinetic profile.
Renal degradation of imipenem results in low
active drug concentrations in the urine and a
marked risk of nephrotoxicity. By combining
imipenem in a 1:1 ratio with cilastatin, an inhib-
itor of the relevant renal enzyme, this metabolism
is blocked and nephrotoxicity is avoided.
Microbial genomics
During the last 30 years, only one new class of
antibacterial agents with a novel mode of action
has been developed: the oxazolidinones, of which
linezolid was the first member. Rapidly increas-
ing knowledge of microbial genetics offers obvi-
ous possibilities to search for new targets and
overcome the previous stagnation. However, the
initial optimism and hopes for immediate thera-
peutic developments resulting from genomic
mapping have been dampened somewhat by the
fact that the products and ⁄ or functions of many
genes are unknown. Identification of gene prod-
ucts and their function requires access to bioin-
formatic systems including and combining
information on genomics and proteomics. Differ-
ent bioinformatic tools have been designed to
search for similarities among different genomes.
However, it may be the case that a large number
of the existing targets for antibacterial activity
have been identified already by other methods.
Another problem in microbial genomics results
from errors in the nucleotide sequences obtained
by many of the early sequencing projects, together
with limited annotation. This emphasises the
urgent need for systematic and continuous anno-
tation of genomic information. Preferably, such
annotation—as well as information about gene
products and their functions—should be collected
centrally in an easily accessible data base.
Fig. 3 shows the steps involved in the exploi-
tation of genomic information to provide a poten-
tial target for antimicrobial drug intervention, and
Target structure and function
Bioinformatics
Bacterial genetics and physiology
Biochemistry and molecular biology
Biochemistry
High throughput screenings
Genome sequence
Potential target list
Validated target list
Inhibition/binding assays
Initial hits
Fig. 3. Summary of the process by which new molecular
targets for antimicrobial agents are identified and exploi-
ted using genomic information.
Cornaglia et al. Research on antibiotic resistance 487
 2004 Copyright by the European Society of Clinical Microbiology and Infectious Diseases, CMI, 10, 473–497
the subsequent identification of drug candidates.
Clearly, a multidisciplinary approach is required.
It could be argued whether research efforts
should be orientated more horizontally or vertic-
ally, but probably the differences in approach will
have little significance.
In general, an antimicrobial target should: (1)
provide specific or highly selective activity against
the microbe with respect to the human host,
together with activity against the desired spec-
trum of pathogens; (2) be essential for the growth
or viability of the pathogen; and (3) have a known
function so that assays and high-throughput
screens can be created. An absolute prerequisite
for this research is an improved knowledge of
microbial physiology and pathogenesis. This
knowledge may also provide opportunities for
novel approaches directed against the pathogenet-
ic mechanisms of infections, rather than targeting
the microorganisms themselves directly.
Gene disruption is a time-consuming process
that, nevertheless, provides valuable in-vivo
information about gene function. This technique
is often required to demonstrate that a gene
product is essential for bacterial growth or viab-
ility, and therefore that it constitutes a likely
candidate molecular target. A variety of genetic
tools to test whether gene products are essential
have been developed. These include:
• random approaches, such as transposon muta-
genesis and conditional lethal mutations;
• sequence-directed approaches, such as plasmid
insertion mutagenesis and allelic exchange
mutagenesis;
• target modulation analysis, such as antisense
RNA and microarray technology.
Approximately half of the genes in bacterial
genomes either lack sufficiently significant
sequence similarity to permit putative functional
assignment, or have likely homologues whose
function is unknown. In neither case can a
function be predicted for the gene product.
However, several genetic, biochemical and com-
putational methods may provide insights into the
function of these proteins. Among these is the
prediction of molecular function from high-reso-
lution X-ray or nuclear magnetic resonance ima-
ging of the molecule.
Once an essential target gene has been identi-
fied, it can be cloned and expressed, and the
protein purified and crystallised to solve the
structure. Knowledge of the three-dimensional
structure of a target may help in understanding
its function, and will also provide the opportunity
for a rational approach to the design of new
antibiotics and inhibitors. Availability of a puri-
fied protein also allows production of monoclonal
antibodies against the target, which are powerful
tools in further studies of its functions.
Conclusions
Finding new molecular targets is merely the first
step in drug discovery. The discovery of a new
antibacterial agent that interacts with these targets
has been empowered by new methodologies such
as molecular modelling, combinatorial chemistry
to synthesise a high diversity and variety of com-
pounds, and high-throughput methods that allow
the rapid screening of hundreds of compounds.
An important issue is allocation of responsibil-
ities and resources between academia and indus-
try. As a general rule, it seems prudent to suggest
that academia should concentrate mostly on
microbial physiology, mechanisms of pathogene-
sis, and target identification and characterisation.
The main role of industry lies in the identification
and screening of potential drug candidates.
Industry has advantages in terms of its access to
excellent bioinformatics units, and extensive com-
puter systems for screening for modes of activity
and potential toxicity.
In summary, antibacterial drug discovery has,
traditionally, relied upon random screening or
modification of known antibacterial agents, often
identified as a result of screening for natural prod-
ucts with antimicrobial activities. These strategies
have failed to deliver sufficient molecular diversity
to counteract the constant increase in antimicrobial
resistance. Hopefully, the technologies mentioned
above should permit a variety of novel agents with
new mechanisms of action to be developed.
W O R K I N G G R O U P 4 : C L I N I C A L
A N D E P I D E M I O L O G I C A L R E S E A R C H
T O E V A L U A T E T H E O U T C O M E O F
A N T I M I C R O B I A L - R E S I S T A N T
I N F E C T I O N S
Introduction
There is a lack of reliable data in Europe con-
cerning the outcomes resulting from antimicrobial
resistance, including attributable mortality, pro-
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longation of hospital care, and the economic
impact on individuals and health care systems.
This information is a prerequisite for estimating
the burden of resistance, and is essential to enable
health system administrators, policy-makers and
health care workers to prioritise, develop and
implement solutions to the problem. The lack of
data concerning these outcomes results, in part,
from problems with the study designs and meth-
ods used in their determination [39,40]. For
example, methods for measuring the economic
impact of resistance are in their infancy, and the
studies available leave many questions unan-
swered [41,42]. Moreover, the impact of antimi-
crobial resistance should be considered from
several viewpoints, namely those of prescribing
physicians, patients, health care service managers
and providers, the pharmaceutical industry, the
general public and governments. Thus, studies to
measure the various defined outcomes must vary
in design according to these viewpoints.
This Working Group addressed the research
objectives and methodological issues relevant to
studies of the clinical and economic outcomes of
resistance.
Study designs
The Working Group identified two types of study
design that are potentially useful for evaluating
interventions to reduce antimicrobial resistance.
First, some participants favoured the use of cohort
studies and case control studies to determine the
burden of infections caused by antimicrobial-
resistant pathogens. The most important problem
with these studies is the difficulty in controlling for
potential confounders. Second, other participants
favoured the use of randomised, controlled trials
to demonstrate the potential benefit of introducing
appropriate intervention measures, such as decis-
ion-support systems (e.g., TREAT), guidelines and
other methods for optimising antimicrobial treat-
ment and infection control measures.
Outcomes
Most published studies on the impact of resist-
ance have limited their assessment to endpoints
such as mortality and length of hospital stay.
Costs and further outcomes after discharge, or
after transfer to other facilities (e.g., rehabilitation
units), are calculated rarely, but should be con-
sidered when evaluating the impact of antimicro-
bial resistance from a public perspective.
The direct medical costs of resistance include
the costs of more expensive antimicrobial agents,
labour and laboratory consumables, the costs of
hospitalisation for extra days necessitated by the
failure of initial therapies, and the cost of isolation
and other infection control measures. To date,
very few studies have provided information
about the costs of care for infections caused by a
given antimicrobial-resistant pathogen in com-
parison to the antimicrobial-sensitive variant of
the same pathogen. Furthermore, because of the
wide variability of health systems in Europe, it is
difficult to compare such information from
different countries. Therefore, it is essential to
develop validated, internationally accepted out-
come measurements that assess the clinical and
economic impact of antimicrobial-resistant infec-
tions and, in turn, provide a means of assessing
the impact of a particular intervention.
Types of infection
Studies are required to investigate the conse-
quences of infections caused by antibiotic-resist-
ant organisms in the community setting, as well
as in the hospital. Research into patient outcomes
associated with nosocomial infection is facilitated
by the availability of better microbiological infor-
mation in hospitals compared with the commu-
nity. Moreover, nosocomial pathogens include
resistant species of high priority, such as MRSA
and Gram-negative multiresistant bacteria. Nev-
ertheless, most antimicrobial prescribing takes
place in the community, and it is also important to
investigate the consequences of infections caused
by relevant resistant pathogens in this setting (i.e.,
meningitis, urinary tract and lower respiratory
tract infections). This research will require com-
puter linkage systems to provide comprehensive
information about resistance in the community
and patterns of antimicrobial prescribing.
Multinational and multidisciplinary approach
The variability between European countries in
antimicrobial prescribing and infection control
measures complicates research in this area.
Researchers should exploit available international
data from hospitals and the community, since
these correspond to the minimum data set
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required. Also, the WHO should include appro-
priate coding for antibiotic-resistant infections in
the ICD-10 system. There is a clear need for close
cooperation between clinicians, microbiologists,
epidemiologists and health care economists to
measure the impact of antimicrobial resistance.
Research infrastructure
Overall, this Working Group reached the follow-
ing consensus with regard to the research infra-
structure required for studying the impact of
antimicrobial resistance:
• multinational and multidisciplinary networks
that investigate variations in practice against
defined outcomes among different countries;
• validated support systems that inform an
appropriate prescribing infrastructure in rela-
tion to local microbial ecology (e.g., TREAT);
• development of validated international,
national and local guidelines and policies;
• collaboration with the WHO to ensure that the
ICD-10 codes address antimicrobial resistance
‘fields’.
Conclusions
The following priorities were formulated for
clinical and epidemiological research to evaluate
the outcome of antibiotic-resistant infections:
• identification of validated outcomes (biological,
clinical and economic) to support the measure-
ment of the antimicrobial resistance burden,
and to assess the benefit and outcomes of
interventions;
• ascertainment of the clinical and socio-econo-
mic burden of antimicrobial resistance associ-
ated with community- and hospital-acquired
(health care-associated) infection;
• mathematical modelling and rigorous system-
atic reviews of the existing evidence linking anti-
microbial resistance to intervention and outcomes;
• development and implementation of high-qual-
ity methodologies for the design and analysis of
antimicrobial resistance and outcome studies;
• development of educational, behavioural and
organisational strategies to improve the man-
agement of infections and reduce the burden of
antimicrobial resistance;
• pharmacokinetic and pharmacodynamic out-
come-based studies that inform prescribing of
generic antimicrobial agents;
• identification of factors that support the susta-
inability of effective strategies to control anti-
microbial resistance (i.e., sustainable and
continuous quality improvement systems).
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Introduction
Ultimately, research into antibiotic resistance
aims to prevent resistance development and
spread of resistance through interventions direc-
ted principally at reducing the overall use of
antibiotics and limiting the transmission of anti-
biotic-resistant infections. The question of how
such interventions should be planned and evalu-
ated through research with a sound scientific
basis is critical. This Working Group attempted to
identify the gaps in the present evidence base,
both in the identification of the risk factors for the
development of antibiotic resistance and in the
design of countermeasures.
Burden of disease
A number of critical issues should be clarified in
order to set the stage for subsequent research.
Importantly, it is necessary to establish the burden
of disease attributable to antibiotic resistance.
Although resistance is recognised as a major
public health threat, data are still needed to
demonstrate the associated costs in terms of excess
morbidity and mortality and economic outcomes.
With the exception of multidrug-resistant tuber-
culosis, for which the evidence is compelling [43],
published data concerning the impact of resistance
remain scarce and incomplete. Data on the burden
of disease are necessary to increase awareness in
medical professionals and in the general public,
and to support requests to policy-makers for
research funds and intervention campaigns.
Is ‘prudent’ use of antibiotics practicable?
The increased use of antibiotics has been blamed
for the increase in antibiotic resistance. Although
‘prudent’ antibiotic use, a term often interpreted
as ‘restricted’ use, has been advocated to coun-
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teract the threat of resistance, its practicability has
not been explored. Health care providers and
prescribers must be convinced that the benefit to
the global community offered by an appropriate
use of antibiotics does not translate into increased
risks for individual patients. It is obvious that
‘prudent’ antibiotic use excludes inappropriate
use, e.g., for the management of viral infections,
or for extended periods in the case of routine
surgical prophylaxis. However, whenever there is
uncertainty in the clinical diagnosis and ⁄ or in the
aetiology of the infection, ‘prudent’ antibiotic use
turns out to be an ill-defined ‘grey area’, and a
matter of personal experience rather than a clear-
cut concept. For some infections, e.g., otitis media,
the early use of antibiotics is still controversial,
and different countries have different medical
practices [44]. Studies to evaluate the outcomes of
these infections according to the therapeutic
strategy employed, including the withholding of
antibiotics, are necessary.
Surveillance programmes
Monitoring changes in the susceptibility of micro-
organisms, and the emergence and spread of
antimicrobial resistance, is a priority for research.
Many local and international antibiotic resistance
surveillance systems have been implemented in
recent years. These systems have diverse aims and
means of funding, e.g., by national governments,
international organisations or pharmaceutical
companies [45]. Surveillance should aim to estab-
lish the need for interventions and to evaluate the
effect of interventions. Accordingly, the results of
surveillance should be disseminated rapidly to
all interested parties. Studies should contribute
to an improvement in the quality of existing
surveillance programmes, and to the design of
new and more focused surveillance programmes.
Surveillance programmes should also integrate
studies in different areas, including molecular
epidemiology and clinical outcomes as well as
descriptive epidemiology. Molecular techniques
should be used to confirm and validate pheno-
typic susceptibility data (e.g., detection of the
mecA gene in MRSA) and to demonstrate the
genetic basis for the emergence and spread of
resistance. The detection of resistance genes, and
of the genetic elements on which they are carried,
is necessary for a deeper insight into the trans-
mission of resistance traits, especially in multire-
sistant isolates. In addition, molecular typing
methods should be used to recognise clusters
and to establish clonal relationships among iso-
lates in order to clearly understand the local and
global spread of resistance. The study of virulence
factors and the detection of virulence markers in
resistant isolates would contribute further to an
understanding of resistance transmission dynam-
ics. The collection of outcome data is also neces-
sary, as these can provide important information
for decision-makers. Outcomes to be considered
include not only clinical endpoints (e.g., morbid-
ity, mortality and length of hospital stay), but also
economic endpoints, such as the costs of newer,
more expensive antibiotics, additional tests, and
prolongations of hospital stay associated with
infections by antibiotic-resistant bacteria.
Integration of information systems
Another priority in the struggle against antibiotic
resistance is research in the field of information
technology aimed at integrating health care and
clinical information systems. Health care system
data bases, such as those maintained by laborat-
ories, pharmacies, hospitals and general practi-
tioners, contain a wealth of information relevant to
the susceptibility of microorganisms and antibiotic
use, both in the hospital and in the community.
Although these data are produced routinely, they
are often not available for an integrated analysis.
Research should be directed towards developing
information technology instruments to integrate
these systems and collate data for epidemiological
studies on antibiotic resistance. These data bases
could be exploited, through the development
of data mining systems, for the early detection
of novel resistance or new trends in resistance
development. In addition, decision-support
systems should be developed and evaluated.
Alternatives to classical epidemiology
Methods of classical epidemiology remain central
to research into antibiotic resistance. These meth-
ods have been used widely to monitor resistance
trends and to design and evaluate intervention
measures, such as vaccination campaigns in the
community and infection control measures in the
hospital. However, in the future, alternative
methodologies may provide a better understand-
ing of resistance and the means for its prediction
Cornaglia et al. Research on antibiotic resistance 491
 2004 Copyright by the European Society of Clinical Microbiology and Infectious Diseases, CMI, 10, 473–497
and control. Although antibiotic use is a primary
factor determining the emergence of resistance,
other risk factors must also be evaluated. Risk-
assessment models that combine classical
epidemiology and mathematical models should
be developed. These would help to identify gaps
in knowledge necessary to evaluate risk factors in
a defined setting.
New mathematical models should be generated
to predict the evolution of resistance [46] and to
evaluate the impact of different control measures
without the need for empirical testing. Import-
antly, the health economic impact of intervention
measures should be amenable to analysis by
mathematical models. These models may allow
prediction of the cost of the intervention and the
reduction in expenses associated with a decrease
(or a stabilisation) of resistance. Finally, investi-
gations aimed at developing neural networks and
artificial intelligence systems should be imple-
mented with the aim of building decision-support
systems for diagnostic and therapeutic purposes.
In particular, these may be targeted at the man-
agement of infections caused by antibiotic-resist-
ant microorganisms.
Conclusions
The priority areas mentioned above are intercon-
nected fields in which research on antibiotic
resistance should concentrate. As all medical and
public health activities should be based on robust
scientific evidence, research should aim to fill
existing gaps in the evidence base concerning the
identification of risk factors for antibiotic resist-
ance development and the evaluation of control
measures. In this regard, epidemiological stud-
ies—integrated with new molecular disciplines
and mathematical modelling—remain central.
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Introduction
This Working Group discussed the current bottle-
necks in European research, the dramatic reduc-
tion in industrial investment into the research and
development of new antibiotics, the need for
partnerships between industry, public health
authorities, academic bodies and regulatory
authorities to support research, the role of scien-
tific societies in training scientists and in promo-
ting and co-ordinating research and associated
information, and the issue of research funding.
The need for new antimicrobials
It must be reaffirmed strongly that there is an
urgent need for new antibacterial agents. Many
new and important challenges are evident already
within current medical practice (e.g., VRE, meth-
icillin- and vancomycin-resistant staphylococci,
multidrug-resistant P. aeruginosa and other glu-
cose-non-fermenting Gram-negative bacilli), and
these are likely to become increasingly pressing in
the near future. These challenges should be
defined clearly and communicated at all levels,
ranging from health care policy-makers to the
customers ⁄patients, as part of an effort to empha-
sise the burden of bacterial infections and their
enduring importance, particularly in the context
of the globalised culture of mega-cities and mass
tourism. The specific contribution of antimicrobial
resistance to the infection problem must be
emphasised, since a greater awareness of this
problem is still needed at the level of health care
providers and the general public, as well as at the
political level.
Education and training of students, physicians
and clinical microbiologists must include the
principles of rational antimicrobial therapy and
the main resistance problems. This represents a
joint task for schools and professional societies,
and important contributions can come from
industry.
Public awareness of the microbial threat and
of antimicrobial resistance should be increased
through educational initiatives that promote an
appropriate physician-driven use of antibiotics.
In this regard, the adjective ‘appropriate’ seems
endowed with a more positive and proactive
meaning. As such, this term might carry the
right message more effectively than the classical
term ‘prudent’, which seems often to simply
advocate an abstention from something. A
strictly economics-based view of the problem
of antimicrobial resistance seems short-sighted
and should not substitute for a comprehensive
clinical and public health viewpoint. Strategies
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aimed only at limiting pharmacy costs may save
money, but more often than not, will decrease
both appropriate and inappropriate antibiotic
use [47].
Many novel antimicrobial agents are likely
to be niche products, endowed with narrow
antibacterial spectra and ⁄ or targeted to specific
clinical problems. Therefore, an important educa-
tional goal will be to change the current attitudes
of physicians and customers towards large-spec-
trum, multi-purpose and user-friendly com-
pounds. Scientific societies must play a leading
role in this process, as they are well-suited to
serve as forums for discussing, harmonising and
monitoring interventions, mostly at the interna-
tional level. It is necessary also to reinforce the
role of these societies in the development of better
clinical and microbiological practices, and in
lobbying specialists in disciplines related to infec-
tious diseases.
The basic directions for research
The problem of antimicrobial resistance, and the
inability of current antibiotics to cover all clinical
needs, suggest two basic directions for research in
this field, namely:
• research on the development of new antimicro-
bial drugs;
• research on the appropriate use of existing
drugs.
These two research lines must be explored in
parallel, since a sufficient development of novel
compounds is unlikely to occur in the next few
years, resulting in a dramatic lag-phase in the
therapeutic possibilities for an increasing number
of bacterial infections, and prompting a more
appropriate use of existing antimicrobials.
Both basic and clinical microbiology appear to
be essential for research on new antimicrobial
compounds, and for better definition of the
appropriate use of existing drugs.
A better understanding is needed of bacterial
physiology and population dynamics, of the role
played by the commensal microflora as a resist-
ance gene pool, and of intrinsic resistance in
opportunistic pathogens. A better understanding
is also needed of the impact of antibiotics on
microbial population dynamics, and of the impact
of biocides on the selection of multiply-resistant
bacterial clones. To this aim, the exchange of
biological materials (strains, genes, etc.) between
researchers should be facilitated, while bearing in
mind the necessity to prevent opportunities for
the acquisition of hazardous organisms for bio-
terrorist purposes. Once again, it must be empha-
sised that scientific societies can play an
important role in this matter by issuing guidelines
for these exchanges, asking national authorities
for less restrictive rules, and playing an active role
in certifying the nature of the exchanges and the
goals of people involved.
The basis for resistance monitoring and appro-
priate use of antibiotics is microbiological diag-
nostics. Faster and more cost-effective detection of
resistance through rapid diagnostic systems is a
prerequisite for the use of better-targeted antibi-
otics.
The need for partnership
There is an urgent need for interdisciplinary and
public–private partnerships to support research
in this area. Exchanges between industry, public
health bodies and academic bodies will entail not
only sharing of costs, but also co-ordination of the
respective research activities.
Unfortunately, and in spite of the urgent need
for new antibiotics, while some pharmaceutical
companies (including Abbott, Bayer, Johnson &
Johnson, GlaxoSmithKline, Novartis and Pfizer)
remain committed to this field of research, many
other companies (such as Aventis, Bristol Myers
Squibb, Lilly, Roche and Wyeth) have terminated
or reduced their research and development
activities in this area drastically. The reasons for
this decline include:
• high failure rates during research and the lack
of developmental compounds;
• preference for research into treatments for
chronic rather than acute conditions;
• increasing generic competition and high regu-
latory hurdles;
• high development costs (e.g., because of the
need to secure a license for multiple indications
for new antibiotics);
• a view that the promises of genomics, high-
throughput screening and combinatorial chem-
istry have not delivered sufficiently.
Other companies (e.g., Cubist and Essential
Therapeutics) have changed their strategies to
focus on the development of a limited number of
compounds rather than invest in research. This
move has taken place because partnerships with
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major companies concerning targets and screen-
ing technologies have proved difficult to achieve.
It must be emphasised that, although research
success rates—in terms of newly discovered
molecules—are low, development success rates
are high. Antibacterial agents have short clinical
development timelines and high success rates,
even though securing a license for multiple
indications usually proves quite costly. This last
point, together with the increased burden of
resistance, means that many novel antibiotics are
likely to be niche products, tailored to specific
clinical needs.
Academic institutions conduct very little
research aimed at developing novel antibiotics,
since they usually lack compound chemistry
resources and knowledge about industrial
research processes. The strengths of academic
research lie in studies on basic bacterial processes
(e.g., antibiotic resistance mechanisms, new tar-
gets for treatments, mutation dissemination and
persistence, pathogenicity and eradication). More-
over, academia has the potential to establish
networks of researchers from disparate fields to
investigate key issues with state-of-the-art tech-
niques, influencing treatment strategies (e.g.,
through the recognition of novel b-lactamases),
and proposing new strategies for the prevention
and treatment of infections (e.g., MRSA). Given
the importance of individual creativity within
academic research, small-scale activities can also
play a fundamental role, either alone or within the
framework of larger forms of co-operation and
multicentre research.
A collaborative effort is needed to address
structural deficits in European research by foster-
ing a culture of co-operation between all stake-
holders (including pharmaceutical companies,
academic researchers and regulatory authorities),
and advancing mutual knowledge and collabor-
ation between public and private research insti-
tutions. The key issues in antibiotic resistance
(rather than individual priorities) must be iden-
tified jointly, and the research priorities and
funding measures defined clearly.
Funding antibiotic research
Funding antibiotic research and interventions for
the appropriate use of antibiotics should be a
combined responsibility of governments, the
pharmaceutical industry, academic bodies and
the EU. Once the key issues in antibiotic resist-
ance have been identified, a clear definition of
priority research goals must take into account the
possibility of public funding (at a sufficient level)
and of complementary private interventions.
In spite of many solemn declarations, Euro-
pean countries have been investing less and less
in research activities during the last few decades.
In the European Council’s Lisbon declaration of
March 2000, all EU member states agreed on a
common strategy for economic growth. Two
years later, the Barcelona European Council
reviewed progress towards the Lisbon goal,
and, in a new declaration, reinforced by further
communications of the European Commission
[48,49], the EU member states agreed that future
EU spending in this field must be increased, with
the aim of approaching 3% of gross domestic
product by 2010. This target matches roughly the
research and development investments by the
other major players. Thus, in 1999, the total
expenditure on research and development, ex-
pressed as a percentage of gross domestic prod-
uct, was 1.8% in Europe, compared with 2.7% in
the USA and 3.1% in Japan. Investment levels in
several European countries are already close to
or beyond these levels, but the profound diver-
sities existing in Europe make this objective quite
ambitious. The gap between Europe and its
major competitors is also significant in terms of
employment, since researchers account for only
5.7 ⁄ 1000 of the industrial workforce in Europe,
as against 8.1 ⁄ 1000 in the USA and 9.1 ⁄ 1000 in
Japan [50].
In addition to being under-resourced, Euro-
pean research is fragmented. The European
Research Area represents a joint effort by the EU
and member states to address structural deficits
in European research, and create a favourable
environment for research and innovation [51]. By
focusing on a limited number of priorities, it is
intended to increase the efficiency and impact of
research.
Academic researchers wishing to secure fund-
ing for research on antibiotic resistance face
several obstacles. Academic research is usually
very expensive, while budgets are limited and
competition is intense. Moreover, antibiotic resist-
ance does not rank high on the lists of priorities
for funding, perhaps partly because of the
absence of strong patient organisations in this
field. Finally, application procedures for public
494 Clinical Microbiology and Infection, Volume 10 Number 5, May 2004
 2004 Copyright by the European Society of Clinical Microbiology and Infectious Diseases, CMI, 10, 473–497
funding are often complicated, and notification of
the outcome of applications is often slow. It
would be useful to establish on-line facilities for
the submission, review and ranking of applica-
tions.
The dramatic reduction in industrial invest-
ment in research and development of new anti-
biotics should prompt appropriate incentives for
industry, particularly in areas of high medical
need. Potential incentives that could be provided
by regulatory authorities include clear and
dependable definitions of the attributes of antibi-
otics regarded as useful and sufficient for regis-
tration, and prolonged patent lives. The
international competitiveness of industry should
be encouraged by the stimulation of multidisci-
plinary research and development, durable part-
nerships, and integration of different stakeholders
representing all the required competencies.
Otherwise, Europe will continue to wit-
ness—for a long time to come—the humiliating
trend of European companies ‘investing across
the ocean’, following the consolidated ‘brain
drain’ trend in favour of a workplace endowed
with a competitive, but more science-friendly
spirit, and fewer ‘over-regulated and over-com-
plicated bureaucracies’ [52].
C O N C L U S I O N S
The measures currently underway within Europe
to prevent and control resistance to antimicrobial
agents are far from sufficient. The consequences
for public health threaten to become acute within
a short time, and ongoing actions should not be
delayed while existing deficiencies in knowledge
are filled. At the same time, further research is
essential, and this Conference has highlighted
areas where resources should be concentrated.
Much research remains necessary at the level of
basic microbiological science, including molecular
epidemiology, mechanisms of resistance and their
transmission, dynamics of clonal spread, inter-
play between resistance and virulence determi-
nants, and microbial genomics. Advances in these
areas will provide valuable data to develop
interventions to prevent and control resistance,
including more efficient forms of rational antibi-
otic design. Microbiological research must encom-
pass the area of ‘resistance ecology’, including
population biology, host population genetics, and
the ecological relationships between resistance in
hospitals, the community, agriculture and the
general environment. Progress has been made in
Europe to improve and co-ordinate laboratory
surveillance of resistance. Nevertheless, further
improvements are essential and, in particular,
there is a need for surveillance focused upon
specific settings and key organisms.
Ultimately, efforts to control resistance aim to
improve the quality of clinical care. The lack of
good-quality, standardised data defining the
impact of resistance on clinical outcomes of
infections, and the associated economic burden,
is an important deficiency in present knowledge.
Well-designed studies covering this field, in both
the community and hospital settings, are neces-
sary to provide data robust enough to convince
health care authorities, governments and the
general public to invest in interventions to control
resistance, and to support the necessary changes
in behaviour, as well as to aid the evaluation of
these interventions.
Although numerous approaches to reducing
resistance through better and more targeted use
of antibiotics have been proposed, research is
required before many of these can be implemen-
ted. For example, further work is required to
develop and evaluate computerised prescriber
decision-support systems and diagnostic tools.
The array of additional interventions requiring
study includes infection control measures, probi-
otics, vaccination and various non-antibiotic
approaches to the treatment of infection. Studies
to evaluate the comparative effectiveness of dis-
ease management strategies and other resistance
control interventions, in terms of clinical and
economic outcomes, as well as antibiotic use and
resistance patterns, are essential. In designing
future studies, researchers should take account of
lessons learned from critical analysis of the
studies performed to date.
The urgent need for new antibiotics with
targeted antibacterial spectra and activity against
multiresistant pathogens is accepted widely.
Thus, the movement of pharmaceutical industry
resources away from this pursuit constitutes a
crisis. The reasons behind the decline in indus-
trial antibiotic development are complex.
Consequently, strategies to reverse it must be
multifactorial and must include consideration of
public–private partnerships, regulatory approval
policies, prescribing practices and diagnostic par-
adigms. Ultimately, the interests of industry and
Cornaglia et al. Research on antibiotic resistance 495
 2004 Copyright by the European Society of Clinical Microbiology and Infectious Diseases, CMI, 10, 473–497
society converge within the long-term aim of
extending the effectiveness of new antibiotics.
All of these efforts hinge on a greater appreci-
ation on the part of health care providers, gov-
ernments and the public of the threat posed by
existing and future levels of antimicrobial resist-
ance. As such, the institution of well-designed
educational programmes continues to be a prior-
ity. In this regard, scientific and professional
societies offer a most valuable resource. It is
regrettable that this field lacks the vocal support
of organised patient groups. Persuasive data from
studies designed to link antibiotic consumption
and long-term health status in individuals (as in
the proposed REBECCA study) may be required
to raise both public and political concern over
antibiotic resistance.
The current fragmentation of European
research resources makes it difficult to gather
adequate competence and complementary skills
to achieve the scientific objectives proposed by
this Conference. The FP6 offers excellent oppor-
tunities to address this situation, although much
groundwork remains to be done to mobilise the
research field and to increase the critical mass of
resources. The discussions at this Conference will
be of central importance to the formulation of
topics for the remaining calls for proposals within
the Priority 1 sub-area, ‘Combating resistance to
antibiotics and other drugs’.
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